SV1997000036A - Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos - Google Patents

Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos

Info

Publication number
SV1997000036A
SV1997000036A SV1997000036A SV1997000036A SV1997000036A SV 1997000036 A SV1997000036 A SV 1997000036A SV 1997000036 A SV1997000036 A SV 1997000036A SV 1997000036 A SV1997000036 A SV 1997000036A SV 1997000036 A SV1997000036 A SV 1997000036A
Authority
SV
El Salvador
Prior art keywords
disorders
present
diseases
mmp
disease
Prior art date
Application number
SV1997000036A
Other languages
English (en)
Inventor
Zandt Michael Van
Brian R Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV1997000036A publication Critical patent/SV1997000036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Abstract

EL PRESENTE INVENTO SE REFIERE A COMPUESTOS INHIBITORIOS DE LA METALOSPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICAS DE LOS MISMOS Y UN METODO PARA TRATAR ENFERMEDADES EMPLEANDO DICHOS COMPUESTOS, LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERAL I, ESTOS COMPUESTOS SON UTILES PARA INHIBIR LAS METALOSPROTEASA DE MATRIZ Y POR LO TANTO, PARA COMBATIR LOS TRASTORNOS DE LOS CUALES CONTRIBUYEN LAS MMP, TALES COMO LA OSREOARTRITIS, LA ARTRITIS REUATOIDEA, AL ARTRITIS SEPTICA, LAS ENFEREMEDADES PERIODONTAELS, ALS ULCERAS DE CORNEA, LA PROTEINURIA, AL ENFERMEDAD DE NEURISMA AORTICA, LA EPIDERMOISIS DISTROFICA, LOS TRASTORNOS QUE PRODUCEN RESPUESTAS INFLAMATORIAS, LAS OSTEOPENIAS EN LAS QUE MEDIA LA ACTIVIDAD DE MMP, LA ENFERMEDAD DE LA ATICULACION TEMPOROANDIBULAR, LAS ENFERMEDADES DESMIELIZANTES DEL SISTEMA NERVIOSO; LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGOS A LA LESION ARTICULAR TRAUMATICA Y TROMBOSIS CORONARIA POR RUPTURA DE PLACA ATEROESCLEROTICA, ASIMISMO ESTE INVENTO PRESENTA COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR DICHOS TRASTORNOS.
SV1997000036A 1996-05-15 1997-05-12 Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos SV1997000036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64849396A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
SV1997000036A true SV1997000036A (es) 1998-07-20

Family

ID=24601014

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000036A SV1997000036A (es) 1996-05-15 1997-05-12 Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos

Country Status (25)

Country Link
EP (1) EP0923530B1 (es)
JP (1) JP3354942B2 (es)
CN (1) CN1100748C (es)
AR (1) AR007098A1 (es)
AT (1) ATE275123T1 (es)
AU (1) AU714207B2 (es)
BR (1) BR9709086A (es)
CA (1) CA2254731C (es)
CO (1) CO5011061A1 (es)
DE (1) DE69730508T2 (es)
DK (1) DK0923530T3 (es)
ES (1) ES2227696T3 (es)
HK (1) HK1021897A1 (es)
HR (1) HRP970244B1 (es)
ID (1) ID17291A (es)
MY (1) MY132463A (es)
PA (1) PA8429701A1 (es)
PE (1) PE66898A1 (es)
PT (1) PT923530E (es)
SV (1) SV1997000036A (es)
TN (1) TNSN97083A1 (es)
TW (1) TW539672B (es)
WO (1) WO1997043239A1 (es)
YU (1) YU18597A (es)
ZA (1) ZA974030B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925637A (en) * 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
GB9922710D0 (en) * 1999-09-24 1999-11-24 Bayer Ag Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
JP2004359546A (ja) * 2001-03-15 2004-12-24 Ono Pharmaceut Co Ltd ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤
WO2002074298A1 (fr) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
AU2009283195A1 (en) * 2008-08-18 2010-02-25 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
WO2015150350A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
CN113979992B (zh) * 2021-11-19 2022-06-24 西安欧得光电材料有限公司 一种3-取代二苯并噻吩及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제

Also Published As

Publication number Publication date
ATE275123T1 (de) 2004-09-15
ES2227696T3 (es) 2005-04-01
WO1997043239A1 (en) 1997-11-20
CN1225621A (zh) 1999-08-11
PE66898A1 (es) 1998-10-22
BR9709086A (pt) 1999-08-03
AU714207B2 (en) 1999-12-23
ZA974030B (en) 1998-02-19
CA2254731C (en) 2004-07-20
ID17291A (id) 1997-12-18
CN1100748C (zh) 2003-02-05
EP0923530B1 (en) 2004-09-01
DK0923530T3 (da) 2005-01-03
AR007098A1 (es) 1999-10-13
TNSN97083A1 (fr) 2005-03-15
TW539672B (en) 2003-07-01
HRP970244B1 (en) 2005-06-30
EP0923530A1 (en) 1999-06-23
CO5011061A1 (es) 2001-02-28
AU3122097A (en) 1997-12-05
PA8429701A1 (es) 2000-05-24
DE69730508T2 (de) 2005-09-29
HK1021897A1 (en) 2000-07-14
DE69730508D1 (de) 2004-10-07
YU18597A (sh) 2001-12-26
MY132463A (en) 2007-10-31
CA2254731A1 (en) 1997-11-20
PT923530E (pt) 2004-12-31
HRP970244A2 (en) 1998-04-30
JP3354942B2 (ja) 2002-12-09
JPH11510821A (ja) 1999-09-21

Similar Documents

Publication Publication Date Title
SV1997000036A (es) Inhibisores de matrices metaloproteasas mediante acidos biaril oxobutiricos sustituidos
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
UY27167A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
PA8493701A1 (es) Compuestos para tratar la obesidad
PA8585001A1 (es) Compuestos de tiazol para el tratamiento de transtornos neurodegenerativos
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
AR014261A1 (es) Compuestos hipolipidemicos de benzotiazepina, composiciones y proceso para su preparacion
AR019692A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-kB.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
BRPI0418006A (pt) composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, e, combinação
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
AR010894A1 (es) Aminoacidos aromaticos biciclicos, un procedimiento para prepararlos, preparaciones farmaceuticas que lo contienen y el empleo de los mismos parapreparar un medicamento que actua como inhibidor de la integrina.
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
HN1997000067A (es) Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
SV1997000037A (es) Inhibisor de matrices de metaloproteasas mediante compuestos sustituidos de fenalquilo,
PA8429301A1 (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz.
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
GT200100169A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular y/o inhibir la actividad de erab/hadh2.
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.

Legal Events

Date Code Title Description
FD Lapse